Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.


Credit available for this activity expires: 6/15/2023


Earn Credit / Learning Objectives & Disclosures: [ Ссылка ]

свернуть